Liver cancer trial tests new chemo combo without embolization

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically-proven HCC or according to EASL criteria * Child-Pugh A or B7 * Disease that is not suitable for resection, ablation or radiofrequency * Performance Status ECOG 0 or 1 * BCLC A/B or C if Performance Status ECOG = 1 * Measurable lesions according to mRECIST criteria * No previous treatment with chemotherapy, radiotherapy or transarterial embolization (with or without chemotherapy) or radioembolisation * Age superior or equal to 18 years * Platelets \> 50,000/mm3, Polynuclear neutrophils \> 1000/mm3, Creatininemia \< 150umol/L, Bilirubinemia \< 5 mg/dL * Absence of heart failure (Ultrasound LVEF \> 50%) * Women of child-bearing age using an adequate method of contraception throughout treatment * Men using an adequate method of contraception throughout the treatment and at least 3 months after the end of treatment * Written informed consent * National health insurance cover Exclusion Criteria: * Advanced tumor disease (extrahepatic except pulmonary micronodules \<7mm of tumoral portal vein thrombosis on positron emission tomography are not a contra-indication.) * Large HCC with liver invasion \>50% * History of other cancer than HCC and excluding cancers known to have been cured for more than 5 years, or basocellular skin tumors or cervical cancer in situ treated with adequate and curative purpose * Advanced liver disease (Child B8, B9 or C) * Contra-indication for the MRI (Pacemaker or neurosensorial stimulator or implantable defibrillator, cochlear implant, ferromagnetic foreing body similar to the nervous structure) * Contra-indication to the injection of the gadolinium-based contrast agents (history of hypersensibility to the gadolinium chelates, meglumine). * Contra-indication to idarubicin (Hypersensibility to active substance or excipients, cardiopathy with myocardial insufficiency of less than 6 months, serious arrhythmias, serious renal or liver failure, yellow fever vaccine or any other live attenuated vaccine, persistente myelosuppression, previous treatments with idarubicin and/or other anthracyclines or anthracenediones at maximum cumulative doses, stomatitis) * Contra-indication to Lipiodol (Hypersensibility, proven hyperthyroidism, tromatic injuries, bleeding or recent bleeding) * Concomitant disease or uncontrolled severe clinical situation * Uncontrolled severe infection * Vascular anatomy makes it impossible to perform hepatic intra-arterial treatments * Pregnancy (Beta HCG positive) or breastfeeding * Patient who for psychological, social, family or geographical reasons cannot be followed regularly * Vulnerable person * Concomitant participation of the patient in another research involving the human person